Literature DB >> 28978567

What Factors Influence Decision-Making about Breast Cancer Chemoprevention among High-Risk Women?

Katherine D Crew1,2,3.   

Abstract

Estrogen exposure is one of the strongest risk factors for breast cancer development. Chemoprevention with selective estrogen receptor modulators (SERM), such as tamoxifen and raloxifene, has been shown in randomized controlled trials to reduce breast cancer incidence by up to 50% among high-risk women. Despite the strength of this evidence, there is significant underutilization of chemoprevention. Given the relatively few modifiable breast cancer risk factors, SERM use provides an important strategy for the primary prevention of this disease. Understanding factors which influence chemoprevention decision-making will inform efforts to implement breast cancer risk assessment and increase chemoprevention uptake in clinical practice. Cancer Prev Res; 10(11); 609-11. ©2017 AACRSee related article by Holmberg et al., p. 625. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28978567     DOI: 10.1158/1940-6207.CAPR-17-0281

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  4 in total

1.  Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study.

Authors:  Carol J Fabian; Lauren Nye; Kandy R Powers; Jennifer L Nydegger; Amy L Kreutzjans; Teresa A Phillips; Trina Metheny; Onalisa Winblad; Carola M Zalles; Christy R Hagan; Merit L Goodman; Byron J Gajewski; Devin C Koestler; Prabhakar Chalise; Bruce F Kimler
Journal:  Cancer Prev Res (Phila)       Date:  2019-08-16

2.  Acceptability of Localized Cancer Risk Reduction Interventions Among Individuals at Average or High Risk for Cancer.

Authors:  Goli Samimi; Brandy M Heckman-Stoddard; Shelley S Kay; Bonny Bloodgood; Kisha I Coa; Jennifer L Robinson; Bethany Tennant; Leslie G Ford; Eva Szabo; Lori Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2019-03-01

3.  Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer.

Authors:  Chelsea Anderson; Hazel B Nichols; Melissa House; Dale P Sandler
Journal:  Cancer Prev Res (Phila)       Date:  2019-08-20

4.  Qualitative analysis of shared decision-making for chemoprevention in the primary care setting: provider-related barriers.

Authors:  Tarsha Jones; Thomas Silverman; Ashlee Guzman; Julia E McGuinness; Meghna S Trivedi; Rita Kukafka; Katherine D Crew
Journal:  BMC Med Inform Decis Mak       Date:  2022-08-04       Impact factor: 3.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.